Article Text

Download PDFPDF

628 Trial in progress: phase I dose-escalation study of VSV-GP (BI 1831169) monotherapy and with ezabenlimab (BI 754091) in patients with locally advanced or metastatic solid tumors
  1. Mercedes Porosnicu1,
  2. Anne-Marie Quinson2,
  3. Abi MacKay3,
  4. Stephan Luecke4 and
  5. Ulrich M Lauer5
  1. 1Wake Forest School of Medicine, Winston Salem, NC, USA
  2. 2Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA
  3. 3Boehringer Ingelheim Ltd, Bracknell, UK
  4. 4Boehringer Ingelheim Pharma GmbH and Co.KG, Biberach, Germany
  5. 5University Hospital Tübingen, Tübingen, Germany


Background Patients with locally advanced or metastatic cancer have poor prognosis despite treatment advancements. VSV-GP (BI 1831169) is a chimeric vesicular stomatitis virus (VSV) with its neurotropic glycoprotein (G) replaced by the non-neurotropic glycoprotein (GP) of the lymphocytic choriomeningitis virus. This live, recombinant oncolytic virus has demonstrated preclinical efficacy as a viral-based immunotherapy due to its interferon-dependent tumor specificity and stimulation of antitumor immune activity. Co-administration of ezabenlimab (BI 754091), a PD-1 targeting checkpoint inhibitor, may enhance antitumor efficacy. The potential synergism of VSV-GP and ezabenlimab will be explored in this first-in-human trial.

Methods This Phase I, open-label, dose-escalation trial will assess the safety, tolerability and early efficacy of VSV-GP given intratumorally (IT), intravenously (IV) or both, as a monotherapy (Part 1) and in combination with ezabenlimab (Part 2) in patients with locally advanced, metastatic or relapsed/refractory solid tumors who previously received or are not candidates for available standard treatment. Key objectives are to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).

Part 1 is a dose-escalation and expansion study of VSV-GP monotherapy administered in four 21-day cycles starting at 5 x 107 median tissue culture infectious dose (TCID50) in Arm A (IT) and at the next tolerated dose level in Arm B (IV) and Arm C (IT + IV). Part 2 is a dose-escalation study of VSV-GP in combination with ezabenlimab. The starting dose of VSV-GP will be one dose level less than the monotherapy RP2D in the corresponding Part 1 arm (IT [Arm D], IV [Arm E], IT + IV [Arm F]) (figure 1). Dose finding will be guided by the Bayesian Optimal Interval design (BOIN).

Primary endpoints include the number of patients experiencing dose-limiting toxicities (DLTs [Part 1/2]) and objective response according to Intratumoral RECIST (itRECIST; Part 1). Secondary endpoints are safety-based (on-treatment DLTs and adverse events). Patients are being recruited. Updates will be provided at the time of presentation.1

Acknowledgements The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment related to the development of the abstract. Devon Else, BSc, of MediTech Media provided writing and editorial support which was contracted and funded by Boehringer Ingelheim International GmbH (BI). BI was given the opportunity to review the abstract for medical and scientific accuracy as well as intellectual property considerations. The 1456.1 study was supported and funded by BI.

Trial Registration NCT05155332


  1. Porosnicu M, et al. Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors. Future Oncol. 2022;18:2627–2638.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.